Text Size

Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01369992
First received: June 8, 2011
Last updated: NA
Last verified: June 2011
History: No changes posted
  Purpose

Cancers are among the most frequent leading causes of death in Taiwan, and many of them show their respective unique epidemiological and pathophysiological features in Taiwanese population. One of the distinguishing features of cancers includes their potential to metastasize outside the primary tumor. Pleural cavity and peritoneum are two of the most frequent sites of metastases when serosal surfaces are involved. The prognoses of such patients are extremely poor with a median survival of months. The understandings of cancer biology of tumor metastasis demand more in-depth studies at the molecular and cell levels. Studies based on cell culture are excellent approaches for this purpose as the cell culture provides a relevant and renewable model for studying the pathological and molecular changes underlying human malignant tumors.


Condition
Metastatic Cancer

Study Type: Observational
Official Title: Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 20
Study Start Date: May 2011
Estimated Study Completion Date: May 2013
Detailed Description:

Due to their easy accessibility, pleural effusions and ascites are two important clinical sources of metastatic cancer cells, which upon isolation, permit comparative studies between the biology nature of primary tumor and metastatic ones. In this study, we will try to isolate cancer cells from human malignant effusions, said to be pleural effusions and/or ascites. We will establish phenotypic alterations along the progression of malignant tumors with serosal metastasis, with special emphasis on expression of some proteases, laminin receptors and transcription factors involved in the process of invasion and metastasis. We would also perform clinical correlations, including tumor type, staging, status of lymph node metastasis and histopathological differentiation and grading, etc.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

cancer patients

Criteria

Inclusion Criteria:

  • cancer patients
  • pleural effusion or peritoneal effusion

Exclusion Criteria:

  • infected and fever patients
  • anticoagulant treatment patients
  • patients don't attend this study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01369992

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Tze-Sian Chan Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Tze-Sian Chan, Department of Gastroenterology
ClinicalTrials.gov Identifier: NCT01369992     History of Changes
Other Study ID Numbers: 99048
Study First Received: June 8, 2011
Last Updated: June 8, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
Metastatic Cancer

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Pleural Effusion
 Neoplastic Processes
Pathologic Processes
Pleural Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 19, 2013